Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. (OPTHF) is a Canadian GMP-compliant pharmaceutical drug manufacturer focused on natural psilocybin and MDMA for regulated mental health therapies. News about Optimi often centers on its role in supplying psychedelic medicines for clinical trials, prescription programs, and specialized treatment pathways in markets such as Australia, Canada, and Israel.
Investors and observers following Optimi’s news flow can expect updates on regulatory milestones, such as Health Canada inspections and Drug Establishment License developments, as well as announcements related to product launches and exports of MDMA and psilocybin capsules. Recent releases have highlighted commercial availability of psilocybin capsules for treatment-resistant depression under Australia’s Authorized Prescriber Scheme, MDMA capsules for PTSD treatment programs, and selection as a supplier for a multicenter PTSD clinical trial sponsored by Sheba Medical Center in Israel.
Corporate news also includes financing transactions, private placements of convertible debentures, and agreements with market-making and investor relations firms. Optimi additionally reports on participation in investor conferences, board changes, and strategic relationships with partners such as Mind Medicine Australia and clinical service providers involved in psychedelic-assisted psychotherapy programs.
This news page aggregates these company-issued updates, giving readers a single view of Optimi’s progress in psychedelic drug manufacturing, its involvement in regulated mental health initiatives, and its capital markets activities. For those tracking developments in pharmaceutical-grade psychedelics and their integration into formal treatment frameworks, Optimi’s news provides insight into how the company positions its MDMA and psilocybin products within evolving regulatory and clinical environments.
Optimi Health Corp has completed the expansion of its analytical laboratory located in Princeton, British Columbia, designed to ensure consistent dosages of natural psilocybin products meeting FDA and EU-GMP standards. The lab, overseen by Chief Science Officer Justin Kirkland, aims to enhance research capabilities and support clients in drug discovery processes. CEO Bill Ciprick emphasized the importance of this facility for operationalizing psychedelic science and the company's revenue strategy. Optimi aims to lead in supplying safe, high-quality psilocybin mushrooms.
Optimi Health Corp. (OTCQX: OPTHF) announced its support for Health Canada's Notice on psilocybin mushrooms, highlighting the importance of drug quality and GMP standards. CEO Bill Ciprick emphasized the company's commitment to producing natural psilocybin and functional mushrooms from its advanced facilities. Optimi is positioned to become a leader in this market, having received permission to handle large quantities of psilocybin. The company will also celebrate the grand opening of its Princeton facility on May 27, inviting stakeholders from various sectors.
Optimi Health Corp. has received approval from Health Canada to modify its Controlled Substances Dealer’s Licence, allowing for an expanded capacity to produce psilocybin and psilocin at its Princeton facility. The amendment permits possession of up to 5,000 kg of dried psilocybin mushrooms and 100 g of psilocin, aiming to support clinical trials for addiction and mental health treatments. The company’s facility now comprises 20,000 square feet of advanced aeroponics systems. Optimi plans a grand opening event on May 27, 2022, inviting the local community and stakeholders.
Optimi Health Corp. is set to inaugurate its new psilocybin cultivation facility on May 27, 2022, with an event for media and stakeholders. The company aims to become the leading supplier of safe, natural psilocybin, leveraging its GMP-grade facility in Canada. With a dealer's license from Health Canada and partnerships with pharmaceutical entities, Optimi is focused on producing scalable mushroom formulations. The grand opening will be livestreamed on Instagram, welcoming community members to celebrate this significant milestone in the psychedelic industry.
Optimi Health Corp. (OTCQB: OPTHF) has initiated the cultivation of GMP-grade psilocybin mushrooms at its facility in Princeton, British Columbia. This milestone aims to supply safe psilocybin products for clinical trials amid increasing market demand. The company, having secured a Controlled Drugs and Substances Dealers License, is collaborating with the IMPACT Clinical Trial Accelerator Program for research on microdosing psilocybin to address mental health issues. A brand and media launch is set for May 2022.
Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) has entered agreements with Kydder Management Group and Generation IACP Inc. for investor relations and market-making services, pending Canadian Securities Exchange approval. Kydder will receive $40,000 monthly for three months, with a renewal option, while GIACP will earn $7,500 monthly for six months, subject to a 3% annual price increase. Optimi is focused on developing functional mushroom products and has received a research exemption for Psilocybin and Psilocin use under Health Canada regulations.
Optimi Health Corp. (CSE: OPTI, OTCQX: OPTHF) has upgraded its common shares to the OTCQX Best Market, enhancing visibility and accessibility for U.S. investors. This upgrade signifies an important milestone for the company, which focuses on developing functional and psychedelic mushroom products for health and wellness. The OTCQX is reserved for established companies meeting high financial standards and best corporate governance practices. Optimi continues its Canadian listing under the symbol OPTI.
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has launched a line of functional mushroom supplements in Canada. The company utilizes high-quality fruiting body mushrooms, including Lion’s Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, to enhance cognitive and physical well-being. Optimi employs an eight-step extraction process to maximize nutrient absorption. Bill Ciprick, CEO, emphasizes their commitment to quality and vertical integration, with plans to cultivate their own mushroom strains in Princeton, BC. Products are available online and will reach select retailers later this year.
Optimi Health Corp. (OTCQB: OPTHF) launches its line of functional mushroom supplements in Canada, targeting health-conscious consumers. The products include Lion’s Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, known for their health benefits. These supplements are created using a unique eight-hour extraction process to enhance efficacy. Optimi aims for vertical integration by cultivating its own mushroom strains in a new facility in Princeton, British Columbia. The company emphasizes high-quality production and customer accessibility through its website and upcoming retail partnerships.
Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) has been added to Health Canada's approved suppliers under the Special Access Program (SAP) for psilocybin, aiming to address mental health issues in Canada. The SAP allows specific medical practitioners to request access to controlled substances for emergency use, paving the way for innovative treatments. The company’s new 10,000 sq. ft. facility in British Columbia has received supply requests, indicating strong market interest. Optimi is dedicated to safe and effective psilocybin products, with plans for a grand opening in May.